Royal Bank of Canada (RY)

257.34
+4.81 (1.90%)
TSX· Last Trade: May 20th, 4:16 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close252.53
Open252.55
Bid257.17
Ask257.35
Day's Range252.55 - 257.91
52 Week Range171.29 - 254.83
Volume4,225,507
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume4,134,301

Chart

About Royal Bank of Canada (RY)

Royal Bank of Canada is a leading financial services institution that provides a wide range of banking and financial solutions to individuals, businesses, and institutions. The bank offers personal and commercial banking services, wealth management, investment banking, and capital markets services. With a robust network of branch locations and digital platforms, it aims to meet the diverse needs of its clients while focusing on innovation and customer service. Royal Bank of Canada is committed to enhancing the financial well-being of its customers and leveraging its expertise to support economic growth in the communities it serves. Read More

News & Press Releases

The #1 Stock I’d Keep Forever Inside a TFSAhttps://www.fool.ca/2026/05/20/the-1-stock-id-keep-forever-inside-a-tfsa-3/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=293d0c06-7437-4608-bffc-9b6500b1f75d
A renewable energy powerhouse with visible business growth potential is an ideal lifelong investment for a TFSA.
Via The Motley Fool · May 20, 2026
Lattice Semiconductor (LSCC) Shares Skyrocket, What You Need To Know
What Happened? Shares of semiconductor designer Lattice Semiconductor (NASDAQ:LSCC) jumped 9.7% in the afternoon session after CEO Ford Tamer's presentation ...
Via StockStory · May 20, 2026
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advancesmarketbeat.com
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year. Sp
Via MarketBeat · May 20, 2026
Why Are GE Aerospace (GE) Shares Soaring Today
What Happened? Shares of industrial conglomerate GE Aerospace (NYSE:GE) jumped 5% in the afternoon session after the company secured a U.S. Air Force contrac...
Via StockStory · May 20, 2026
2 Canadian Stocks Primed to Surge in 2026https://www.fool.ca/2026/05/20/2-canadian-stocks-primed-to-surge-in-2026-3/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=c2278e26-0c0b-4c54-88b0-3de1c295b9da
Two Canadian stocks with powerful fundamental catalysts are poised to deliver exceptional gains in 2026.
Via The Motley Fool · May 20, 2026
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentummarketbeat.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf
Via MarketBeat · May 20, 2026
Are Wall Street Analysts Predicting Church & Dwight Stock Will Climb or Sink?
Church & Dwight has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Via Barchart.com · May 20, 2026
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advancesmarketbeat.com
Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted supplemental new drug application for sickle cell disease during a presentation at the 2026 R
Via MarketBeat · May 19, 2026
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growthmarketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo
Via MarketBeat · May 19, 2026
Addus HomeCare Says License Moratorium Won’t Slow Personal Care Growth, M&Amarketbeat.com
Addus HomeCare (NASDAQ:ADUS) executives said a new federal moratorium on certain home health licenses should have little effect on the company’s growth plans, while highlighting continued improvement in personal care services trends and ongoing acquisition opportunities. Speaking at an RBC healthca
Via MarketBeat · May 19, 2026
The Top 3 Canadian ETFs I’m Considering for 2026https://www.fool.ca/2026/05/18/the-top-3-canadian-etfs-im-considering-for-2026-4/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=25cd2c0c-46f6-488b-bde2-c68bf6a19b62
The top three Canadian ETFs are reliable passive monthly income providers to investors seeking instant diversification.
Via The Motley Fool · May 18, 2026
3 TSX Stocks Built for Higher-for-Longer Interest Rateshttps://www.fool.ca/2026/05/18/3-tsx-stocks-built-for-higher-for-longer-interest-rates-2/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=f3e584ae-832d-4039-9a8a-5b57b6744f8c
Three TSX stocks are strong buys if a higher-for-longer interest rate environment is forthcoming.
Via The Motley Fool · May 18, 2026
Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.
Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.
Via Barchart.com · May 18, 2026
Do Wall Street Analysts Like Thermo Fisher Scientific Stock?
While Thermo Fisher Scientific has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
Via Barchart.com · May 18, 2026
A 6.4% Dividend Stock Paying Out Monthlyhttps://www.fool.ca/2026/05/16/a-6-4-dividend-stock-paying-out-monthly/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=f00e4996-41ba-4c8d-810f-7bc9541c86f6
A high-yield stock operating within a specialized niche in the real estate sector pays monthly dividends.
Via The Motley Fool · May 16, 2026
RBC Q1 Deep Dive: Aerospace and Defense Momentum Drives Revenue Growth, Margin Outlook Stable
Bearings manufacturer RBC Bearings (NYSE:RBC) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 18.3% year on year to $518 million. Guidanc...
Via StockStory · May 16, 2026
The Best Dividend Stocks to Buy and Hold Foreverhttps://www.fool.ca/2026/05/15/the-best-dividend-stocks-to-buy-and-hold-forever-3/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=5d908b5e-9e1c-413f-8585-40d16ebfb182
Canadians can form a lasting, self-sustaining income engine with the best dividend stocks.
Via The Motley Fool · May 15, 2026
Here’s the Average TFSA and RRSP at Age 45https://www.fool.ca/2026/05/15/heres-the-average-tfsa-and-rrsp-at-age-45-4/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=21efb3ca-cbda-4265-ae53-f60b27a4085a
The average TFSA and RRSP at age 45 is far from ideal but Canadians in their mid-life have ample time to secure their financial futures.
Via The Motley Fool · May 15, 2026
Why Repligen (RGEN) Stock Is Trading Up Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 2.9% in the afternoon session after RBC Capital resumed co...
Via StockStory · May 15, 2026
RBC (RBC) Q4 2026 Earnings Call Transcriptfool.com
RBC (RBC) Q4 2026 Earnings Call Transcript
Via The Motley Fool · May 15, 2026
RBC Bearings Q4 Earnings Call Highlightsmarketbeat.com
RBC Bearings (NYSE:RBC) reported a record fiscal fourth quarter for 2026, with management pointing to strong aerospace and defense demand, steady industrial growth and continued debt reduction as key themes from the period. Chairman, President and Chief Executive Officer Dr. Michael Hartnett said f
Via MarketBeat · May 15, 2026
Crude Oil Surges 3%; RBC Bearings Earnings Top Viewsbenzinga.com
US stocks down, S&P 500 falls 1%; Dow down 1.08%, NASDAQ down 1.42%. Energy shares up 1.5%; materials stocks down 2.1%. RBC Bearings beats Q1 estimates.
Via Benzinga · May 15, 2026
RBC Bearings Reports Q4 2026 Results: Full Earnings Call Transcriptbenzinga.com
Via Benzinga · May 15, 2026
3 TSX Stocks Built to Earn, Pay, and Endurehttps://www.fool.ca/2026/05/15/3-tsx-stocks-built-to-earn-pay-and-endure-2/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=eb42377e-f8cc-4fb6-97ff-2d5e039302ec
Three TSX stocks are compelling options for risk-averse investors prioritizing dividend safety and reliability over high yields.
Via The Motley Fool · May 15, 2026
RBC Bearings (NYSE:RBC) Beats Q1 CY2026 Sales Expectations
Bearings manufacturer RBC Bearings (NYSE:RBC) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 18.3% year on year to $51...
Via StockStory · May 15, 2026